

RECEIVED
CENTRAL FAX CENTER
FEB 08 2007

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Please amend the above-identified application as follows.



1-71. (Cancelled)

72. (Currently amended) A method for treating superficial cancer of the bladder derived from the bladder epithelium, comprising:


contacting the luminal surface of the bladder with a pretreatment composition comprising a transduction enhancing agent; and

~~subsequently~~ further contacting the luminal surface of the bladder with a composition comprising ~~[[an]]~~ a replication competent oncolytic virus comprising a urothelium-specific promoter;

wherein cells of the bladder epithelium are transduced and the transduction enhancing agent has the following general formula (I) ~~or the following general formula (II):~~



wherein X is a sulfur or oxygen atom, each R² is independently hydrogen or a moiety represented by:




and R¹ represents an alkyl or alkenyl group wherein R¹ comprises from 10 to 14 carbons or a cyclohexylhexyl group; and

~~wherein the luminal surface of the bladder is contacted with the pretreatment composition for at least 10 minutes.~~

73. (Currently amended) The method of Claim 72, wherein R¹ comprises at least 12 carbon atoms.

74. (Original) The method of Claim 72, wherein each R² is hydrogen.

75. (Original) The method of Claim 72, wherein the transduction enhancing agent has the chemical formula:



wherein n is a positive integer.

76. (Original) The method of Claim 75, wherein n is 11 or greater.

77. (Original) The method of Claim 75, wherein n is 11.


78. (Original) The method of Claim 77, wherein the pretreating composition comprises about 0.025 to about 0.4 % by weight of the transduction enhancing agent.

79. (Original) The method of Claim 72, wherein the luminal surface of the bladder is contacted with the pretreatment composition for at least 20 minutes.

80. (Currently amended) The method of Claim [[79]]72, wherein the luminal surface of the bladder is contacted with the composition comprising the replication competent oncolytic virus for 15 minutes or less.

81. (Currently amended) The method of Claim [[79]]72, wherein the luminal surface of the bladder is contacted with the composition comprising the replication competent oncolytic virus for 10 minutes or less.

82. (Original) The method of Claim 72, wherein the transduction enhancing agent has the chemical formula:




wherein n is a positive integer.

83. (Original) The method of Claim 72, wherein the oncolytic virus is an oncolytic adenovirus.

84. (Original) The method of Claim 83, wherein the oncolytic adenovirus is CG8840.


85. (Original) The method of Claim 72, wherein the oncolytic virus composition comprises at least 4×10^{10} viral particles.

86. (Original) The method of Claim 72, wherein the transduction enhancing agent has the chemical formula:



where R^1 represents an alkyl or alkenyl group.

87. (Currently amended) The method of Claim 86, wherein R^1 is represented by:




88-95. (Cancelled)

96. (New) A method for transducing bladder epithelium cells, comprising:


contacting the luminal surface of the bladder with a pretreatment composition comprising a transduction enhancing agent; and

subsequently contacting the luminal surface of the bladder with a composition comprising a replication competent adenovirus;

wherein the transduction enhancing agent has the following general formula (I):



wherein X is oxygen atom, each R² is independently hydrogen or a moiety represented by:




wherein R¹ comprises from 10 to 14 carbons or a cyclohexylhexyl group.

97. (New) The method of Claim 96, wherein R¹ comprises 12 carbon atoms.

98. (New) The method of Claim 96, wherein each R² is hydrogen.

99. (New) The method of Claim 96, wherein the transduction enhancing agent has the chemical formula:




wherein n is a positive integer.

100. (New) The method of Claim 99, wherein n is 11 or greater.

101. (New) The method of Claim 99, wherein n is 11.

102. (New) The method of Claim 99, wherein the pretreating composition comprises about 0.025 to about 0.4 % by weight of the transduction enhancing agent.

103. (New) The method of Claim 96, wherein the transduction enhancing agent has the chemical formula:



wherein n is a positive integer.


104. (New) The method of Claim 103, wherein n is 6.

105. (New) A method for transducing bladder epithelium cells, comprising:

contacting the luminal surface of the bladder with a pretreatment composition comprising a transduction enhancing agent; and

further contacting the luminal surface of the bladder with a composition comprising a replication competent adenovirus;

wherein the transduction enhancing agent has the following general formula (I):




wherein X is oxygen, each R² is independently hydrogen and R¹ represents an alkyl or alkenyl group.

106. (New) The method of Claim 105, wherein R¹ comprises 12 carbon atoms.

107. (New) The method of Claim 105, wherein each R² is hydrogen.

108. (New) The method of Claim 105, wherein the transduction enhancing agent has the chemical formula:




wherein n is a positive integer.

109. (New) The method of Claim 105, wherein n is 11 or greater.

110. (New) The method of Claim 105, wherein n is 11.

111. (New) The method of Claim 105, wherein the pretreating composition comprises about 0.025 to about 0.4 % by weight of the transduction enhancing agent.

112. (New) The method of Claim 105, wherein the transduction enhancing agent has the chemical formula:



wherein n is a positive integer.

113. (New) The method of Claim 112, wherein n is 6.

114. (New) The method of Claim 105, wherein the luminal surface of the bladder is contacted with a pretreatment composition comprising a transduction enhancing agent and a replication competent adenovirus at the same time.

115. (New) The method of Claim 105, wherein the luminal surface of the bladder is contacted with a pretreatment composition comprising a transduction enhancing agent prior to contact with a replication competent adenovirus.